APPLICATION
ANDA204722
TYPE
ANDA
ORIGINAL APPROVAL
2017-01-11
LATEST ACTION
2025-03-26
ROUTE
ORAL
DOSAGE FORM
TABLET, ORALLY DISINTEGRATING
MARKETING STATUS
Prescription
Products
RIZATRIPTAN BENZOATEPrescription
RIZATRIPTAN BENZOATE EQ 5MG BASE · TABLET, ORALLY DISINTEGRATING · ORAL
RIZATRIPTAN BENZOATEPrescription
RIZATRIPTAN BENZOATE EQ 10MG BASE · TABLET, ORALLY DISINTEGRATING · ORAL
Approval history
2025-03-26Labeling · Supplement 2 · standardAP
2017-01-11UNKNOWN · OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.